PharmaFacts for Case Managers

July 2025

Brought to you by the publishers of ***CareManagement***

Yeztugo

- *Generic Name:* Lenacapavir
- *Company*: Gilead Sciences, Inc.
- *Treatment For:* Pre-exposure prophylaxis of HIV to reduce the risk of getting HIV-1 in adults and adolescents.
- *Description*: A human immunodeficiency virus type 1 (HIV-1) capsid inhibitor for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1.
- *Drug Class:* Selective HIV-1 capsid inhibitors.
- *Dosing Information:* Tablets for oral use (300 mg), injection for subcutaneous use in a single-dose vial (463.5 mg/1.5 mL). The initial dose consists of 2 Yeztugo injections (Day 1) and 2 Yeztugo tablets (Days 1 and 2). After completing the initial dose, 2 Yeztugo injections every 6 months.

Black Box Warning
Risk of drug resistance with use of Yeztugo for HIV-1 pre-exposure prophylaxis in undiagnosed HIV-1 infection. Individuals must be tested for HIV-A before initiating Yeztugo and before each subsequent injection.

- *Side Effects:* Injection site reaction, headache, and nausea.
- *Full Prescribing Information:* https://www.gilead.com/-/media/files/pdfs/medicines/hiv/yeztugo/yeztugo_pi.pdf

Zusduri

- *Generic Name:* Mitomycin
- *Company*: UroGen Pharma Ltd.
- *Treatment For:* Low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG-IR-NMIBC), in adults who have previously received bladder surgery to remove the tumor, and it did not work or is no longer working.
- *Description:* A sustained-release, hydrogel-based formulation of mitomycin for intravesical treatment of LG-IR-NMIBC.
- *Drug Class:* Antibiotic/antineoplastic.
- *Dosing Information:* Zusduri is administered by intravesical instillation only. Recommended dose is 75 mg (56 mL) instilled once weekly for six weeks into the bladder via urinary catheter.
- *Side Effects:* The most common side effects, including laboratory abnormalities, that occurred in patients were increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.
- *Full Prescribing Information:* https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215793s000lbl.pdf

Widaplik

- *Generic Name:* Telmisartan, Amlodipine, and Indapamide
- *Company*: George Medicines
- *Treatment For:* Hypertension in adult patients to lower blood pressure. Widaplik may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals.
- *Description:* Widaplik is a fixed-dose combination tablet of an angiotensin II (telmisartan), a calcium channel blocker (amlodipine), and a diuretic (indapamide).
- *Dosing Information:* Widaplik is available in three fixed-dose combinations: 10 mg telmisartan/1.25 mg amlodipine, 0.625 mg indapamide; 20 mg telmisartan/2.5 mg amlodipine/1.25 indapamide; 40 mg telmisartan/5 mg amlodipine/2.5 mg indapamide. Initial treatment of hypertension: start with Widaplik (10 mg/ 1.25 mg/0.625 mg) or Widaplik (20 mg/2.5 mg/1.25 mg) once daily. Initial treatment for elderly patients: start with Widaplik (10 mg/1.25 mg/0.625 mg) Titrate dose: Adjust dose based on clinical response at intervals of approximately 2 weeks. Maximum dose: Widaplik 40 mg/5 mg/2.5 mg orally once daily.
- *Side Effects:* Dizziness, headache, fatigue, nausea, hypotension, cough.

Black Box Warning
Widaplik has a warning for fetal toxicity. When pregnancy is detected, discontinue Widaplik as soon as possible [see Warnings and Precautions]. Drugs that act directly on the renin-angiotensin-aldosterone system can cause injury and death to the developing fetus.

- *Full Prescribing Information:* https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219423s000lbl.pdf

Xifyrm

- *Generic Name:* Meloxicam
- *Company:* Azurity Pharmaceuticals, Inc.
- *Treatment For:* Use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Because of delayed onset of analgesia, XIFYRM alone is not recommended for use when rapid onset of analgesia is required.
- *Description*: Nonsteroidal, anti-inflammatory drug (NSAID).
- *Dosing Information:* 30 mg once daily, administered by intravenous bolus injection over 15 seconds.

Black Box Warning

- ***Cardiovascular Risk:*** NSAIDs cause an increased risk of serious cardiovascular thrombotic events including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. XIFYRM is contraindicated in the setting of coronary artery bypass graft surgery.
- ***Gastrointestinal Risk:*** NSAIDs cause an increased risk of serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

- *Side Effects:* Cardiovascular thrombotic events, GI bleeding, ulceration, and perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, hematologic toxicity.
- *Full Prescribing Information:* https://www.xifyrm.com/full-prescribing-information

Emrelis

- *Generic Name:* Telisotuzumab vedotin-tllv
- *Company*: Verastem Oncology
- *Treatment For:* Non-squamous non-small cell lung cancer with high c-Met protein overexpression.
- *Description*: Emrelis is a first-in-class, c-Met protein-directed antibody-drug conjugate.
- *Drug Class:* Antineoplastic.
- *Dosing Information:* Emrelis is 1.9 mg/kg (up to a maximum of 190 mg for patients greater than or equal to 100 kg) administered as an intravenous infusion over 30 minutes every 2 weeks until disease progression or unacceptable toxicity.
- *Side Effects:* Peripheral neuropathy, interstitial lung disease, pneumonitis, ocular surface disorders, infusion-related reactions, embryo-fetal toxicity, fatigue, decreased appetite, swelling in hands, feet, ankles, and legs.
- *Full Prescribing Information:* https://www.rxabbvie.com/pdf/emrelis_pi.pdf

Imaavy

- *Generic Name:* Nipocabimab-aahu
- *Company*: Johnson & Johnson Innovative Medicines
- *Treatment For:* Generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or antimuscle-specific tyrosine kinase (MuSK) antibody positive.
- *Description:* Imaavy is a human IgG1 monoclonal antibody that binds to neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG levels.
- *Dosing Information:* The recommended initial dosage of IMAAVY is 30 mg/kg administered once via intravenous infusion over at least 30 minutes. Two weeks after the initial dosage, a maintenance dosage of 15 mg/kg via intravenous infusion is given over at least 15 minutes. Continue the maintenance dosage every two weeks thereafter.
- *Side Effects:* Infections, hypersensitivity reactions, Infusion-related reactions, cough, sore throat, burning or pain on urination.
- *Full Prescribing Information:* https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761430s000lbl.pdf